Boehringer Ingelheim registers Phase Ib/II trial pairing obrixtamig, pumitamig in SCLCSep 28Trial updateBioNTech SEBoehringer Ingelheim
Arcus Biosciences advances casdatifan combinations, reports $775M cash at midyear 2026Aug 5Quarterly updateArcus Biosciences, Inc.AstraZeneca
BioNTech names Guido Oelkers CEO, trims 2026 revenue guidance in Q2 updateAug 4Quarterly updateBioNTech SE
BMS posts PRIME-HCC results; adds SOTYKTU label update, Phase 3 lung trialJul 2Weekly roundup, 7 itemsBristol Myers Squibbcisplatin
Sign inSign in